NASDAQ:ASMB - Assembly Biosciences Stock Price, Price Target & More

$43.61 -0.22 (-0.50 %)
(As of 04/25/2018 08:00 AM ET)
Previous Close$43.83
Today's Range$42.97 - $45.00
52-Week Range$18.60 - $67.36
Volume90,583 shs
Average Volume278,635 shs
Market Capitalization$895.42 million
P/E RatioN/A
Dividend YieldN/A
Beta0.74

About Assembly Biosciences (NASDAQ:ASMB)

Assembly Biosciences logoAssembly Biosciences, Inc. operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States. It is involved in the development of core protein allosteric modulators that modulate the HBV core protein at various points in the viral lifecycle. The company also develops microbiome program, a platform that includes the identification and selection process to strain isolation and growth under current good manufacturing practice conditions; and a patent pending delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. In addition, it engages in the development of product candidates for various disease indications, such as ulcerative colitis, Crohn's disease, irritable bowel syndrome, non-alcoholic steatohepatitis, immuno-oncology, and clostridium difficile infections by using its microbiome platform. It has a collaboration agreement with Allergan Pharmaceuticals International Limited for the development and commercialization of selected microbiome gastrointestinal programs. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in Carmel, Indiana.

Receive ASMB News and Ratings via Email

Sign-up to receive the latest news and ratings for ASMB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:ASMB
CUSIP92282210
Phone317-210-9311

Debt

Debt-to-Equity RatioN/A
Current Ratio9.13%
Quick Ratio9.13%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$9.02 million
Price / Sales98.78
Cash FlowN/A
Price / CashN/A
Book Value$5.62 per share
Price / Book7.76

Profitability

EPS (Most Recent Fiscal Year)($2.41)
Net Income$-42,800,000.00
Net Margins-474.65%
Return on Equity-60.16%
Return on Assets-31.79%

Miscellaneous

Employees79
Outstanding Shares20,430,000

How to Become a New Pot Stock Millionaire

Assembly Biosciences (NASDAQ:ASMB) Frequently Asked Questions

What is Assembly Biosciences' stock symbol?

Assembly Biosciences trades on the NASDAQ under the ticker symbol "ASMB."

How were Assembly Biosciences' earnings last quarter?

Assembly Biosciences (NASDAQ:ASMB) issued its quarterly earnings results on Monday, November, 17th. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, missing the consensus estimate of ($0.49) by $0.84. Assembly Biosciences had a negative net margin of 474.65% and a negative return on equity of 60.16%. View Assembly Biosciences' Earnings History.

What price target have analysts set for ASMB?

3 equities research analysts have issued 1-year target prices for Assembly Biosciences' stock. Their predictions range from $35.00 to $75.00. On average, they expect Assembly Biosciences' stock price to reach $53.3333 in the next year. View Analyst Ratings for Assembly Biosciences.

Are investors shorting Assembly Biosciences?

Assembly Biosciences saw a decrease in short interest in March. As of March 15th, there was short interest totalling 355,682 shares, a decrease of 34.0% from the February 28th total of 539,065 shares. Based on an average daily volume of 189,244 shares, the short-interest ratio is currently 1.9 days. Currently, 2.1% of the company's stock are short sold.

Who are some of Assembly Biosciences' key competitors?

Who are Assembly Biosciences' key executives?

Assembly Biosciences' management team includes the folowing people:
  • Mr. Derek A. Small, Co-Founder, Pres, CEO & Director (Age 42)
  • Dr. Richard J. Colonno Ph.D., Chief Scientific Officer (Age 68)
  • Mr. Thomas E. Rollins M.S., M.B.A., Chief Devel. Officer and Head of the Microbiome Program (Age 62)
  • Mr. David J. Barrett CPA, Strategic Advisor Role (Age 42)
  • Dr. Miguel S. Barbosa Ph.D., Strategic Advisor (Age 60)

Has Assembly Biosciences been receiving favorable news coverage?

Headlines about ASMB stock have trended somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Assembly Biosciences earned a coverage optimism score of 0.14 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 45.21 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

How do I buy shares of Assembly Biosciences?

Shares of ASMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Assembly Biosciences' stock price today?

One share of ASMB stock can currently be purchased for approximately $43.61.

How big of a company is Assembly Biosciences?

Assembly Biosciences has a market capitalization of $895.42 million and generates $9.02 million in revenue each year. The biopharmaceutical company earns $-42,800,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Assembly Biosciences employs 79 workers across the globe.

How can I contact Assembly Biosciences?

Assembly Biosciences' mailing address is 11711 NORTH MERIDIAN STREET SUITE 310, CARMEL IN, 46032. The biopharmaceutical company can be reached via phone at 317-210-9311 or via email at [email protected]


MarketBeat Community Rating for Assembly Biosciences (ASMB)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  129 (Vote Outperform)
Underperform Votes:  118 (Vote Underperform)
Total Votes:  247
MarketBeat's community ratings are surveys of what our community members think about Assembly Biosciences and other stocks. Vote "Outperform" if you believe ASMB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASMB will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Assembly Biosciences (NASDAQ:ASMB) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Assembly Biosciences in the last 12 months. Their average twelve-month price target is $53.3333, suggesting that the stock has a possible upside of 22.30%. The high price target for ASMB is $75.00 and the low price target for ASMB is $35.00. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldBuyBuyBuy
Consensus Rating Score: 2.332.672.673.00
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $53.3333$48.3333$40.00$35.00
Price Target Upside: 22.30% upside15.78% downside10.93% downside13.20% upside

Assembly Biosciences (NASDAQ:ASMB) Consensus Price Target History

Price Target History for Assembly Biosciences (NASDAQ:ASMB)

Assembly Biosciences (NASDAQ:ASMB) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/13/2018Chardan CapitalDowngradeBuy -> Neutral$35.00 -> $50.00HighView Rating Details
3/8/2018Jefferies GroupBoost Price TargetBuy$75.00MediumView Rating Details
1/5/2018B. RileyInitiated CoverageNeutral -> Neutral$35.00HighView Rating Details
8/19/2016William BlairInitiated CoverageMarket Perform -> OutperformN/AView Rating Details
(Data available from 4/25/2016 forward)

Earnings

Assembly Biosciences (NASDAQ:ASMB) Earnings History and Estimates Chart

Earnings by Quarter for Assembly Biosciences (NASDAQ:ASMB)

Assembly Biosciences (NASDAQ:ASMB) Earnings Estimates

2018 EPS Consensus Estimate: ($3.22)
2019 EPS Consensus Estimate: ($3.38)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.96)($0.96)($0.96)
Q2 20182($0.77)($0.71)($0.74)
Q3 20181($0.74)($0.74)($0.74)
Q4 20181($0.78)($0.78)($0.78)
Q1 20191($0.82)($0.82)($0.82)
Q2 20191($0.84)($0.84)($0.84)
Q3 20191($0.85)($0.85)($0.85)
Q4 20191($0.87)($0.87)($0.87)

Assembly Biosciences (NASDAQ ASMB) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017Q3 2017($0.88)($0.71)$1.25 million$2.66 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.78)$2.36 millionViewN/AView Earnings Details
5/8/2017Q1 2017($0.03)($0.81)$12.50 million$0.68 millionViewN/AView Earnings Details
3/2/2017Q4 2016($0.67)ViewN/AView Earnings Details
11/9/2016Q3 2016($0.67)ViewN/AView Earnings Details
8/9/2016Q2 2016($0.59)ViewN/AView Earnings Details
5/10/2016Q1 2016($0.64)ViewN/AView Earnings Details
3/11/2016Q4 2015($0.45)ViewN/AView Earnings Details
11/9/2015Q3 2015($0.38)ViewN/AView Earnings Details
8/13/2015Q2 2015($0.41)ViewN/AView Earnings Details
5/8/2015Q1 2015($0.64)ViewN/AView Earnings Details
3/16/2015Q4 2014($0.38)ViewN/AView Earnings Details
11/17/2014Q3 2014($0.49)($1.33)ViewN/AView Earnings Details
8/14/2014Q2 2014($0.55)($0.52)ViewN/AView Earnings Details
4/2/2014($0.28)($0.29)ViewN/AView Earnings Details
8/9/2013Q2 2013($1.10)($1.20)ViewN/AView Earnings Details
5/10/2013Q1 2013($1.10)($1.10)ViewN/AView Earnings Details
11/13/2012Q3 2012($1.80)($2.05)ViewN/AView Earnings Details
8/9/2012Q2 2012($2.80)($2.95)ViewN/AView Earnings Details
5/9/2012Q1 2012($2.65)($3.30)ViewN/AView Earnings Details
11/14/2011Q3 2011($2.45)($2.50)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Assembly Biosciences (NASDAQ:ASMB) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Assembly Biosciences (NASDAQ ASMB) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 19.60%
Institutional Ownership Percentage: 76.34%
Insider Trading History for Assembly Biosciences (NASDAQ:ASMB)
Institutional Ownership by Quarter for Assembly Biosciences (NASDAQ:ASMB)

Assembly Biosciences (NASDAQ ASMB) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/2/2018William R RingoDirectorSell1,000$49.32$49,320.0020,465View SEC Filing  
3/1/2018William R RingoDirectorSell1,000$56.37$56,370.00View SEC Filing  
2/1/2018William R RingoDirectorSell1,000$46.86$46,860.00View SEC Filing  
1/2/2018William R RingoDirectorSell1,000$45.04$45,040.00View SEC Filing  
12/1/2017William R RingoDirectorSell1,000$49.37$49,370.0020,465View SEC Filing  
11/1/2017William R RingoDirectorSell1,000$29.55$29,550.00View SEC Filing  
10/16/2017William R RingoDirectorSell1,000$33.70$33,700.00View SEC Filing  
2/11/2016Derek A. SmallCEOBuy10,000$5.53$55,300.00634,391View SEC Filing  
5/27/2014Russell H EllisonCEOBuy13,000$0.92$11,960.00View SEC Filing  
5/23/2014David Jonathan BarrettCFOBuy6,980$0.86$6,002.80View SEC Filing  
5/23/2014Russell H EllisonCEOBuy20,000$0.91$18,200.00View SEC Filing  
5/21/2014Russell EllisonCEOBuy10,000$0.87$8,700.0025,000View SEC Filing  
5/20/2014David Jonathan BarrettCFOBuy40,000$0.88$35,200.0040,000View SEC Filing  
2/5/2013Russell H EllisonCEOBuy15,000$2.55$38,250.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Assembly Biosciences (NASDAQ ASMB) News Headlines

Source:
DateHeadline
 Brokerages Expect Assembly Biosciences (ASMB) Will Post Quarterly Sales of $1.88 Million Brokerages Expect Assembly Biosciences (ASMB) Will Post Quarterly Sales of $1.88 Million
www.americanbankingnews.com - April 21 at 4:52 AM
 Analysts Anticipate Assembly Biosciences (ASMB) Will Announce Earnings of -$0.76 Per Share Analysts Anticipate Assembly Biosciences (ASMB) Will Announce Earnings of -$0.76 Per Share
www.americanbankingnews.com - April 19 at 5:19 AM
Assembly Biosciences (ASMB) Lowered to Sell at BidaskClubAssembly Biosciences (ASMB) Lowered to Sell at BidaskClub
www.americanbankingnews.com - April 18 at 10:42 AM
Assembly Biosciences (ASMB) Receives Consensus Rating of "Hold" from AnalystsAssembly Biosciences (ASMB) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 15 at 7:15 AM
BidaskClub Upgrades Assembly Biosciences (ASMB) to "Sell"BidaskClub Upgrades Assembly Biosciences (ASMB) to "Sell"
www.americanbankingnews.com - April 13 at 5:29 PM
Chardan: Assembly Biosciences Hep B Antiviral Data Positive, But Undifferentiated From Competitor Johnson & JohnsonChardan: Assembly Biosciences Hep B Antiviral Data 'Positive,' But Undifferentiated From Competitor Johnson & Johnson
finance.yahoo.com - April 13 at 3:46 PM
Assembly Biosciences (ASMB) Downgraded by Chardan Capital to "Neutral"Assembly Biosciences (ASMB) Downgraded by Chardan Capital to "Neutral"
www.americanbankingnews.com - April 13 at 10:37 AM
Assembly Bios lead candidate shows positive action in early-stage HBV studiesAssembly Bio's lead candidate shows positive action in early-stage HBV studies
seekingalpha.com - April 12 at 11:19 AM
Was Assembly Biosciences Inc’s (NASDAQ:ASMB) Earnings Growth Better Than The Industry’s?Was Assembly Biosciences Inc’s (NASDAQ:ASMB) Earnings Growth Better Than The Industry’s?
finance.yahoo.com - April 12 at 11:19 AM
Assembly Biosciences (ASMB) Upgraded at BidaskClubAssembly Biosciences (ASMB) Upgraded at BidaskClub
www.americanbankingnews.com - April 12 at 10:22 AM
Assembly Biosciences to Host Conference Call on April 12 to Review ABI-H0731 Interim Phase 1b DataAssembly Biosciences to Host Conference Call on April 12 to Review ABI-H0731 Interim Phase 1b Data
www.nasdaq.com - April 11 at 11:00 AM
Assembly Bio conference call tomorrow to review ABI-H0731 dataAssembly Bio conference call tomorrow to review ABI-H0731 data
seekingalpha.com - April 11 at 11:00 AM
Assembly Biosciences (ASMB) Cut to Sell at BidaskClubAssembly Biosciences (ASMB) Cut to Sell at BidaskClub
www.americanbankingnews.com - April 4 at 9:55 AM
Assembly Biosciences (ASMB) Expected to Post Quarterly Sales of $1.88 MillionAssembly Biosciences (ASMB) Expected to Post Quarterly Sales of $1.88 Million
www.americanbankingnews.com - April 4 at 4:28 AM
Assembly Biosciences (ASMB) Says ABI-H0731 Phase 1b Interim Data Accepted as a Late-Breaker Poster at EASLAssembly Biosciences (ASMB) Says ABI-H0731 Phase 1b Interim Data Accepted as a Late-Breaker Poster at EASL
www.streetinsider.com - April 3 at 10:42 AM
Assembly Biosciences Appoints Jackie Papkoff, PhD, Senior Vice President, Chief Scientific Officer MicrobiomeAssembly Biosciences Appoints Jackie Papkoff, PhD, Senior Vice President, Chief Scientific Officer Microbiome
finance.yahoo.com - April 3 at 10:42 AM
William R. Ringo Sells 1,000 Shares of Assembly Biosciences (ASMB) StockWilliam R. Ringo Sells 1,000 Shares of Assembly Biosciences (ASMB) Stock
www.americanbankingnews.com - April 2 at 10:41 PM
Active-Investors: Blog Exposure - Assembly Biosciences to Present ABI-H0731 Phase-1b Interim Data at The International Liver CongressActive-Investors: Blog Exposure - Assembly Biosciences to Present ABI-H0731 Phase-1b Interim Data at The International Liver Congress
www.finanznachrichten.de - April 2 at 10:47 AM
Assembly Biosciences Inc (ASMB) Expected to Announce Earnings of -$0.79 Per ShareAssembly Biosciences Inc (ASMB) Expected to Announce Earnings of -$0.79 Per Share
www.americanbankingnews.com - April 2 at 5:12 AM
Jefferies Group Initiates Coverage on Assembly Biosciences (ASMB)Jefferies Group Initiates Coverage on Assembly Biosciences (ASMB)
www.americanbankingnews.com - April 1 at 10:48 AM
Assembly Biosciences (ASMB) & Blueprint Medicines (BPMC) Financial SurveyAssembly Biosciences (ASMB) & Blueprint Medicines (BPMC) Financial Survey
www.americanbankingnews.com - March 31 at 7:50 AM
Assembly Biosciences Inc (ASMB) Short Interest UpdateAssembly Biosciences Inc (ASMB) Short Interest Update
www.americanbankingnews.com - March 31 at 3:18 AM
Assembly Biosciences Sees Unusually High Options Volume (ASMB)Assembly Biosciences Sees Unusually High Options Volume (ASMB)
www.americanbankingnews.com - March 30 at 7:07 AM
Assembly Biosciences (ASMB) Upgraded to "Buy" at BidaskClubAssembly Biosciences (ASMB) Upgraded to "Buy" at BidaskClub
www.americanbankingnews.com - March 26 at 3:13 PM
Assembly Biosciences (ASMB) Downgraded by BidaskClub to BuyAssembly Biosciences (ASMB) Downgraded by BidaskClub to Buy
www.americanbankingnews.com - March 23 at 8:28 PM
Assembly Biosciences Inc (ASMB) Given Average Rating of "Buy" by AnalystsAssembly Biosciences Inc (ASMB) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - March 21 at 10:44 AM
$1.68 Million in Sales Expected for Assembly Biosciences Inc (ASMB) This Quarter$1.68 Million in Sales Expected for Assembly Biosciences Inc (ASMB) This Quarter
www.americanbankingnews.com - March 18 at 9:28 AM
BidaskClub Upgrades Assembly Biosciences (ASMB) to Strong-BuyBidaskClub Upgrades Assembly Biosciences (ASMB) to Strong-Buy
www.americanbankingnews.com - March 17 at 7:16 PM
Assembly Biosciences (ASMB) Downgraded by Zacks Investment ResearchAssembly Biosciences (ASMB) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 14 at 5:32 PM
Assembly Biosciences Target of Unusually Large Options Trading (ASMB)Assembly Biosciences Target of Unusually Large Options Trading (ASMB)
www.americanbankingnews.com - March 14 at 7:33 AM
Assembly Biosciences (ASMB) Stock Rating Upgraded by Zacks Investment ResearchAssembly Biosciences (ASMB) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 13 at 5:48 PM
Assembly Biosciences Announces Additions to Management Team and Board of DirectorsAssembly Biosciences Announces Additions to Management Team and Board of Directors
finance.yahoo.com - March 12 at 9:16 AM
Assembly Biosciences Inc Expected to Earn Q1 2019 Earnings of ($0.82) Per Share (ASMB)Assembly Biosciences Inc Expected to Earn Q1 2019 Earnings of ($0.82) Per Share (ASMB)
www.americanbankingnews.com - March 12 at 7:15 AM
Assembly Biosciences Inc to Post Q2 2018 Earnings of ($0.77) Per Share, Jefferies Group Forecasts (ASMB)Assembly Biosciences Inc to Post Q2 2018 Earnings of ($0.77) Per Share, Jefferies Group Forecasts (ASMB)
www.americanbankingnews.com - March 12 at 3:40 AM
Assembly Biosciences (ASMB) PT Raised to $75.00 at Jefferies GroupAssembly Biosciences (ASMB) PT Raised to $75.00 at Jefferies Group
www.americanbankingnews.com - March 8 at 6:34 PM
Assembly Biosciences to Present at Cowen’s 38th Annual Healthcare ConferenceAssembly Biosciences to Present at Cowen’s 38th Annual Healthcare Conference
finance.yahoo.com - March 5 at 11:01 AM
Bogle Investment Management L P DE Acquires New Stake in Assembly Biosciences Inc (ASMB)Bogle Investment Management L P DE Acquires New Stake in Assembly Biosciences Inc (ASMB)
www.americanbankingnews.com - March 4 at 4:58 AM
Insider Selling: Assembly Biosciences Inc (ASMB) Director Sells 1,000 Shares of StockInsider Selling: Assembly Biosciences Inc (ASMB) Director Sells 1,000 Shares of Stock
www.americanbankingnews.com - March 2 at 7:16 PM
Zacks: Brokerages Anticipate Assembly Biosciences Inc (ASMB) Will Announce Quarterly Sales of $1.68 MillionZacks: Brokerages Anticipate Assembly Biosciences Inc (ASMB) Will Announce Quarterly Sales of $1.68 Million
www.americanbankingnews.com - March 1 at 11:24 AM
Assembly Biosciences Inc (ASMB) Shares Bought by EAM Investors LLCAssembly Biosciences Inc (ASMB) Shares Bought by EAM Investors LLC
www.americanbankingnews.com - February 28 at 1:56 PM
Assembly Biosciences Inc (ASMB) Given Consensus Rating of "Buy" by AnalystsAssembly Biosciences Inc (ASMB) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - February 24 at 9:54 AM
Victory Capital Management Inc. Purchases 11,830 Shares of Assembly Biosciences Inc (ASMB)Victory Capital Management Inc. Purchases 11,830 Shares of Assembly Biosciences Inc (ASMB)
www.americanbankingnews.com - February 24 at 4:52 AM
Stock Traders Buy High Volume of Call Options on Assembly Biosciences (ASMB)Stock Traders Buy High Volume of Call Options on Assembly Biosciences (ASMB)
www.americanbankingnews.com - February 22 at 7:44 AM
 Brokerages Anticipate Assembly Biosciences Inc (ASMB) Will Announce Quarterly Sales of $1.68 Million Brokerages Anticipate Assembly Biosciences Inc (ASMB) Will Announce Quarterly Sales of $1.68 Million
www.americanbankingnews.com - February 12 at 5:28 AM
Investor Expectations to Drive Momentum within Regal Beloit, Kaiser Aluminum, AngioDynamics, Mulesoft, Assembly Biosciences, and Woodward — Discovering Underlying Factors of InfluenceInvestor Expectations to Drive Momentum within Regal Beloit, Kaiser Aluminum, AngioDynamics, Mulesoft, Assembly Biosciences, and Woodward — Discovering Underlying Factors of Influence
finance.yahoo.com - February 6 at 8:30 AM
Assembly Biosciences (ASMB) Stock Rating Upgraded by ValuEngineAssembly Biosciences (ASMB) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - February 3 at 2:36 PM
Assembly Biosciences Inc (ASMB) Director Sells $46,860.00 in StockAssembly Biosciences Inc (ASMB) Director Sells $46,860.00 in Stock
www.americanbankingnews.com - February 2 at 10:02 PM
Assembly Biosciences Inc (ASMB) Given Consensus Rating of "Hold" by AnalystsAssembly Biosciences Inc (ASMB) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - January 30 at 9:39 AM
Zacks: Brokerages Expect Assembly Biosciences Inc (ASMB) Will Post Earnings of -$0.79 Per ShareZacks: Brokerages Expect Assembly Biosciences Inc (ASMB) Will Post Earnings of -$0.79 Per Share
www.americanbankingnews.com - January 24 at 1:36 PM
Commit To Purchase Assembly Biosciences At $40, Earn 41.3% Annualized Using OptionsCommit To Purchase Assembly Biosciences At $40, Earn 41.3% Annualized Using Options
www.nasdaq.com - January 24 at 8:51 AM

SEC Filings

Assembly Biosciences (NASDAQ:ASMB) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Assembly Biosciences (NASDAQ:ASMB) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Assembly Biosciences (NASDAQ ASMB) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.